- Pope's holy year causes transport jitters for Rome
- American 14-year-old talent signs MLS pro deal with Man City awaiting
- Nadal wants to lose fear factor after winning Rome opener
- UN official says Israel closure of Gaza crossings 'completely crippling' aid
- Panama Papers law firm boss Ramon Fonseca dead
- Eurovision draws street protests calling for Israel's ejection
- Stormy Daniels denies cashing in on claimed tryst with Trump
- Spain govt vows to block hostile BBVA bid for rival bank
- In south Brazil, race on to deliver aid ahead of new storms
- NHL Maple Leafs fire Keefe as coach after first-round exit
- Porsche recalls thousands of Taycans over faulty batteries
- Sanchez escapes through dust and gravel for nervy Giro triumph
- RFU warn England rugby star Billy Vunipola after Mallorca arrest
- Forest have 'moved on' from failed points deduction appeal, says Nuno
- Dyche unable to 'crack on' with Everton rebuild during takeover saga
- Stormy Daniels denies cashing in on claims of tryst with Trump
- Trump's son Barron, 18, named Republican delegate
- Mbappe gets ready to say goodbye as PSG digest Champions League exit
- Nadal squeezes past qualifier Bergs in Rome opener
- Boeing passenger plane exits runway in Senegal injuring 11
- Chessum in doubt for England's tour of Japan and New Zealand
- UK's Cameron calls for Israel to produce 'clear plan' for Rafah
- Cate Blanchett to be honoured at San Sebastian film festival
- Olympic torch relay in Marseille offers 'solidarity' with Ukraine
- Jorginho targets silverware after signing new Arsenal deal
- Stormy Daniels back in the Trump trial hot seat
- Scientists win World Food Prize for work on Global Seed Vault
- London, Frankfurt stocks hit record highs on rate-cut hopes
- Israel hits Rafah despite US warning on arms transfers
- Atletico win appeal over racist abuse sanction
- Nepal's nature threatened by new development push: conservationists
- Russell returns from injury to bolster Bath's bid for Premiership title
- Cate Blanchett to be honoured by San Sebastian film festival
- Charity warns Italy's ban on NGO planes risks lives
- Celtic captain McGregor urges Hoops to 'stay calm' against Rangers
- Olympic javelin champion Chopra targets 90m mark in Doha
- Norris backs McLaren to mount 2025 F1 title bid after Miami win
- London, Frankfurt hit record highs on rate-cut hopes
- UK's Cameron urges NATO countries to boost defence spending
- Bank of England holds rate at 16-year high, signals looming cut
- Spanish court shelves Shakira tax fraud case
- Bayern face uncertain future after Champions League exit
- Rafah struck after Biden warning on arms transfers
- European stocks stutter before Bank of England rate call
- Italian tennis star Giorgi retires
- Inevitable Madrid continue Champions League love affair
- Nissan net profit nearly doubles despite China challenges
- Spain vows to block BBVA's hostile bid for rival bank
- Olympic torch relay sets off in Marseille
- Blackstone wins bidding war for UK music rights firm
US company withdraws ALS drug after it fails in trial
Amylyx Pharmaceuticals announced Thursday it was withdrawing its approved treatment against the deadly neurodegenerative disease ALS after clinical data found no evidence the drug worked.
In a statement, the US company said it would discontinue its market authorizations for Relyvrio/Albrioza, using the brand names of the medicine in the US and Canadian markets.
"While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS and other neurodegenerative diseases," said the company's co-CEOs Joshua Cohen and Justin Klee in a statement.
The company also said it was reducing its workforce "by approximately 70 percent" as it focused on another experimental drug for use against ALS, and on repurposing Relyvrio for other conditions. It added it would continue to make Relyvrio available for patients who wish to keep using the treatment, through a "free drug program."
The news follows data from a clinical trial of 664 ALS patients announced in March, which found no significant differences in outcomes between those on the treatment group and those who received a placebo.
It was a big blow for patients with amyotrophic lateral sclerosis, sometimes called Lou Gehrig's disease after the famous baseball player, which devastates nerve cells in the brain and spinal cord.
ALS affects about two people per 100,000 every year, causing progressive loss of motor and cognitive function. Most patients die within five years of their diagnosis.
Relyvrio's approval by the US Food and Drug Administration in 2022 was controversial and based on the results of a single trial that involved just 137 participants.
The FDA itself noted there was "residual uncertainty about the evidence of effectiveness" -- but "given the serious and life-threatening nature of ALS and the substantial unmet need, this level of uncertainty is acceptable in this instance and consideration of these results in the context of regulatory flexibility is appropriate."
- Patient groups backed approval -
Advocacy groups also mounted a major campaign sending a petition to the FDA with tens of thousands of signatures urging approval. Once it became available, Amylyx reportedly announced an eye-watering list price of $158,000 per year in the US, drawing criticism.
Patient groups in Europe watched with desperation at the bureaucratic delays.
When the European Union drug watchdog later announced it was rejecting Relyvrio, the decision was slammed as "an affront" by angry French patients, who say they "don't have time to wait." France later relented, offering conditional approval in November.
"We commend Amylyx for pulling Relyvrio off the market, while still ensuring that people living with ALS can access the drug if they believe it is helping them," said the US-based ALS association, which had lobbied for the drug's approval and funded its research.
"Safe and potentially effective treatments can be made accessible rapidly until further research can confirm their efficacy," it added.
For now, there remain only a handful of treatments available.
Riluzole, FDA approved in 1995, prolongs life approximately three months. Edaravone, FDA approved in 2017, has been found to slow disease progression and improve survival.
And in 2023, the regulatory body approved tofersen, a gene therapy treatment that targets those ALS cases that are caused by mutations in the SOD1 gene.
K.Thomson--BTB